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Abstract 
The objective is to identify attributes of ADHD stimulant medications that inﬂuence treatment preferences of 
parents of children and adolescents with ADHD across six European countries, using a discrete choice experiment 
(DCE). Different attributes (and associated levels) of stimulant therapies were identiﬁed through literature review 
and clinician input. Attributes included duration and degree of symptom control after each dose, frequency of 
medication dosing, potential for treatment to be abused, the side effects of vomiting, loss of appetite, and sleep dis-
turbance. Attributes and levels were combined using an orthogonal design to produce a number of discrete hypo-
thetical treatments. Parents were recruited via patient panels in different countries and asked to complete a survey. 
DCE data were analyzed using conditional logit models to explore the impact of each attribute on participants’ 
choices. Six hundred individuals (220 parents of adolescents and 380 parents of children) participated. All attributes were 
signiﬁcant predictors of choice (p \ 0.01). ‘Degree of symptom control’ was the most important attribute whereby the odds of 
choosing ‘very much improved symptoms’ compared with ‘minimally improved’ was 4.85 [95 % conﬁdence interval  
(CI) = 4.28–5.49] for the adolescent group and 6.37 (95 % CI = 5.79–7.01) for the child group. Some inter-country differences 
emerged, e.g., achieving the best degree of symptom control was more important to parents in some countries than others. In 
conclusion, the study showed that duration and degree of symptom control were the most important aspects of treatment for 
parents in all countries. The ﬁndings revealed cultural differences in the relative importance of attributes.  
Keywords ADHD . Patient preference . Discrete choice experiment . Stimulant therapy  
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Introduction  
Stimulant treatments for attention-deﬁcit/hyperactivity disorder (ADHD) have been shown to provide effective 
relief of symptoms and improve functioning and health-related quality of life (QoL) for many patients [1–3]. The 
therapies currently available vary in terms of chemical composition and delivery formulation, pharmacokinetic and 
pharmacodynamic proﬁle, recommended dosing schedule, and efﬁcacy proﬁle. In addition, stimulant treatment 
effects can vary between individuals in relation to each of these characteristics. This may lead to different patients 
responding to therapies in different ways. When choosing between the different options, it is recommended that 
prescribing decisions take into account the preferences of parents and the affected child [2] in terms of differences in 
dosing schedules, efﬁcacy proﬁles, and other issues.  
Patient/parent preferences between different stimulant therapies may be inﬂuenced by a range of factors. In 
addition to the characteristics described above, different treatments for ADHD can have different side-effect rates 
and proﬁles. Common adverse events include nausea, loss of appetite, and sleep problems [2], which also vary from 
individual to individual. Substance abuse
 
is common in patients diagnosed with ADHD [2], and reports have 
highlighted the potential for abuse of ADHD stimulant medications [4, 5]. The average age of individuals misusing 
ADHD stimulant medication in a US National Survey on Drug Use and Health was 19.5 years [5] and, of 1,025 
students in a US university, 16 % had abused or misused medication, most commonly immediate-release methyl-
phenidate (MPH) [4]. Students reported several reasons for misuse including improving academic achievements, 
sharpening attention and sustaining concentration, and reducing hyperactivity. Of 21,465 individuals who reported 
non-medical use of ADHD medications, 8.5 % were aged 12–17 years [5]. The potential for misuse may impact on 
patient/parent preferences when selecting between different therapies.  
Standardized methods for eliciting an individual’s treatment preferences are widely used in healthcare research 
[6]. Such methods provide information regarding the importance of different attributes of interventions to determine 
patients’ treatment choices and levels of adherence. Preference research has examined parents’ views regarding the 
importance of attributes such as dosing schedules, degree of effective symptom control, modes of administration, 
side effects, and acceptability of treatments  
for ADHD [7–14]. These studies typically employed stated preference surveys [discrete choice experiments (DCEs)] 
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to elicit parents’ preferences. Waschbusch et al. [12] conducted a DCE to explore parent preferences for the treat-
ment of medication-naı¨ve children. Parents were presented with descriptions of treatment combinations with varied 
treatment outcomes and costs. The study identiﬁed two groups of parents: the majority (70 %) preferred to avoid 
medication, while the remaining parents based their treatment decisions on what they perceived to be the best 
clinical outcomes. Further analyses predicted that parents who favored treatment in general would speciﬁcally prefer 
behavioral therapy, alone or in combination with medication, over stimulant medication alone. Mu¨hlbacher et al. 
[8] explored six aspects of ADHD treatment with 219 participants (parents and patients) in Germany. The aim was 
to understand what would constitute the ideal treatment for ADHD from the point of view of parents and patients. A 
range of treatment attributes were studied, from improvements in QoL to variation in speciﬁc treatment character-
istics (duration of effect, side effects, dosage, discretion, emotional state, and social institution). Overall, parents and 
patients preferred treatment that resulted in a balanced mood, being able to go out and socialize, and reduced ADHD 
symptoms.  
Lloyd et al. [9] explored the preferences of parents of young people with ADHD in the UK regarding different MPH 
formulations. Parents preferred an oral, once-a-day therapy (compared with three times daily administration or a 
transdermal patch), rapid onset of action, and longer duration of ADHD symptom control. Glenngard et al. [13] 
employed DCE to assess the preferences and willingness to pay of 285 patients with ADHD (or the parents of 
children and adolescents) for different treatment attributes, including symptom control, side effects, dosing and cost. 
All attributes were signiﬁcant predictors of choice (p \ 0.01), with symptom control and side effects considered the 
most important treatment attributes. Conner et al. [14] explored preferences of non-stimulant ADHD medication and 
product proﬁles among children and adolescents with ADHD in the USA, and their caregivers, using a conjoint 
analysis survey. Treatment attributes included onset of effect, black box medication warning, improvement in 
oppositionality, clinician-and teacher-reported improvements in ADHD symptoms and a range of side effects. For 
caregivers, somnolence and improvement in oppositionality were the most important attributes. For children and 
adolescents themselves (aged 10–17 years), somnolence and improvement in symptoms at school were most 
important. Although somnolence was an important attribute, aspects relating to efﬁcacy were generally more critical 
drivers of preference than non-serious side effects. These studies have demonstrated that maximizing ADHD 
symptom control and minimizing side effects are important to patients with ADHD and their parents [7–9, 14]. The 
body of DCE research to date has explored attributes that relate to functioning in an ideal ADHD treatment [8, 10], 
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and characteristics of different MPH formulations such as speed of onset and dosing ﬂexibility [9].  
 
[Table 1 A list of ﬁnal attributes and levels]  
 
The current study extends existing knowledge in two ways. First, it includes speciﬁc treatment attributes, such as 
substance abuse liability and speciﬁc side effects of stimulant medication that have not been systematically explored 
in preference research to date. Second, it provides the ﬁrst cross-national comparison of patient preferences 
regarding ADHD treatments, comparing responses from participants in six European countries (France, Germany, 
Italy, the Netherlands, Spain, and the UK) where different approaches to ADHD management may result in different 
ADHD treatment patterns.  
 
Methods  
Development of the DCE survey  
A focused literature search was conducted with the speciﬁc goal of identifying important elements or attributes of 
ADHD stimulant medications to be included in the preference survey, including reviews of the published literature, 
the Food and Drug Administration (FDA)-approved package inserts/labels (US), and the Summary of Product 
Characteristics produced by the European Medicines Agency (EMA) for ADHD stimulant treatments. A targeted 
literature search was conducted in PubMed, EMBASE.com, and Google Scholar to identify articles published 
between 1997 and 2009 presenting evidence regarding the common side effects of treatment and information on the 
abuse of prescription medication in ADHD. Literature search terms included ‘treatment’ OR ‘quality of life’ OR 
‘patient reported outcome’ OR ‘preference’ OR ‘clinical trial’ among other terms and ‘ADHD’ OR ‘inattention’ OR 
‘hyperactivity’ OR ‘impulsivity’. The narrow scope and targeted nature of the search meant that only a limited 
number of highly relevant articles were retrieved. Of 12 articles initially identiﬁed, four were relevant for the present 
study [9, 15–17].  
Attribute identiﬁcation  
Potential attributes were generated from the literature review in consultation with an ADHD expert on the research 
team (ESB). The list was then shortened to the ﬁnal study attributes based on further study team and expert review. 
The number of attributes was limited to seven in order to avoid an excessive number of preference item 
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combinations, which would create an excessive burden on the participants. The attributes to be tested in the ﬁnal list 
included: (a) duration of ADHD symptom control; (b) degree of ADHD symptom control; (c) potential for treatment 
abuse; (d) frequency of administration; (e) risk of vomiting; (f) risk of loss of appetite; and (g) risk of sleep 
disturbance.  
Each attribute was described using three levels considered to reﬂect a relevant and realistic range for that attribute 
by the study team (Table 1).  
The attribute describing the potential for treatment abuse was only included in the survey for parents of adolescents 
(at least 13 years old). It was considered inappropriate and clinically irrelevant to ask parents of younger children 
about this.  
Final DCE survey  
The DCE included a background questionnaire and a clinical history form. The seven attributes and three levels 
were combined using a published orthogonal array (available at: http://neilsloane.com/oadir/). Participants were 
presented with 18 pairs of hypothetical treatment choices differing systematically in terms of attributes and levels, 
and were asked to indicate whether they preferred treatment A or B in each choice set. Parents were also asked to 
categorize their child’s current treatment in terms of the attributes included in the survey, by stating which level best 
described their child’s current medication. All study-related documentation was translated into each target country’s 
local language using one forward-and one back-translation methodology in line with best practice [18]. The surveys 
were also culturally adapted in each country after translation. Participants in each country were debriefed and asked 
to comment on the accuracy of the documents. The documents were revised accordingly in each language following 
the cognitive debrief ﬁndings.  
The survey was piloted with ﬁve parents in the UK. Parents completed the survey and were asked to comment on 
the clarity of the instructions, appropriateness of choices/questions, the face validity of the choices, and overall 
length of the survey. Following this exercise, no changes were made to the survey. The study protocol and all case-
report forms including the ﬁnal survey were approved by the Independent Institutional Review Board (A2106).  
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Data collection  
Sample  
Parents and/or primary carers of children (aged 6–12 years) or adolescents (aged 13–17 years) with ADHD were 
recruited in France, Germany, Italy, the Netherlands, Spain, and the UK (N = 100 per country). These countries, 
covering Northern and Southern parts of Western Europe, were selected in order to sample broadly across differing 
national and cultural approaches to the diagnosis and management of ADHD. The study team aimed to recruit 
equally sized samples of parents of children and adolescents. The study employed a convenience sample recruited 
and screened by a specialist patient recruitment agency and were invited to complete the online questionnaire after 
giving online consent. The panel approached parents who had previously indicated that they had a child with ADHD 
and would be willing to take part in research. Parents reported the child’s diagnosis on his/her behalf. To minimize 
the possibility of recruiting non-ADHD patients in the sample, all participants completed an eligibility screener 
before completing the survey. This screener was designed with clinician input to help validate the sample 
recruitment. Further, the specialist patient recruitment agency runs continuous validation procedures to ensure the 
accuracy of their sample. Parents were excluded if the child or adolescent had been diagnosed with a signiﬁcant 
psychiatric disorder (other than ADHD) that inﬂuenced the child or adolescentinawaythatcould not be distinguished 
from the impact of ADHD, including pervasive developmental disorder, Asperger’s syndrome, autism, depression, 
and/ or conduct disorder; this determination was based on the self-report of parents. Participants received nominal 
compensation after completing the survey (approximately €2.50).  
Statistical analysis  
Conditional logit models were estimated to explore the impact of each attribute (independent variable) on the 
participants’ choices (dependent variable). Analyses were separated by country and as a total sample. The 
conditional logit model evaluated choice responses after conditioning them on the attributes of the other treatment 
alternatives available within the choice set. Hence, if, for example, ‘Treatment option A’ was preferred in the choice 
set #1, this preference was conditional on the attributes of ‘Treatment option B’. The coefﬁcients obtained from the 
logit model provided an estimate of the (log) odds ratios (ORs) of preference for treatment attributes. In addition, 
8 
 
interactions were explored to see whether there were any country-speciﬁc differences in the preferences of parents. 
In the conditional logit model, participants serve as their own controls. As a result, estimates cannot be confounded 
by omitted between-patient covariates, making the estimates less sensitive to model speciﬁcation than those based 
on random intercept models [19]. As there is no heterogeneity within an individual on time invariant covariates, the 
baseline characteristics are absorbed within individual-level ﬁxed effects. All analyses were conducted in Stata vs  
9.0.  
Results  
Participant characteristics  
A total of 600 participants (220 parents of adolescents and 380 parents of children with ADHD) completed all study 
questionnaires. Demographics and background clinical data are presented by country (Table 2). Overall, the 
majority of respondents in both cohorts were female (61.8 and 59.7 %), with a modal age ranging from 30 to 44 
years. The age ranges of adolescents and children were similar in all countries. Parents reported a wide range of 
different treatments in use by their children/adolescents. The most commonly used treatments were long-and short 
acting MPH, particularly in the UK (adolescent 85 %, child 94 %), the Netherlands (adolescent 89 %, child 94 %), 
and Germany (adolescent 88 %, child 99 %). Amphetamine use was higher in Spain, Italy, and France compared 
with the UK, Germany, and Netherlands (Table 2). More than half of all patients had also received non-
pharmacological therapy. The majority of parents of adolescents (66 %) reported that they were aware that some 
ADHD medications have abuse potential.  
[Table 2 Socio-demographic proﬁle of the sample by country (short version)] 
 
Parents’ perception and ratings of ADHD current treatment attributes are presented in Table 3. Approximately 40–
45 % of parents reported that the treatment effect lasted for 4–6 h each day. At least 39 % of parents reported that 
patients were taking ADHD medication once daily; however, only 22 % of parents of adolescents and 16 % of 
parents of children reported that the effect of ADHD medication taken by their child lasted for 12 h. The least 
common dosing regimen was three times daily across the whole sample, and more adolescents were prescribed a 
once-daily formulation compared with children. In Spain, France, and Italy, 19–35 % of parents reported that their 
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child or adolescent experienced vomiting due to their ADHD medication. High rates of sleep disturbance (total 
adolescents 41 % and children 45 %) and appetite loss (total adolescents 46 % and children 43 %) were also 
reported.  
DCE results  
Table 4 presents the results of the DCE for parents’ treatment choices in terms of ORs and associated 95 % conﬁ-
dence intervals (95 % CIs), showing the order of importance of a given attribute when selecting a treatment. The 
analyses indicated the preference for different attributes and improvements in the levels of those attributes for 
ADHD therapies. The ﬁndings had face validity in that parents preferred treatments that improved outcomes or 
reduced side effects or risks, and all attributes were signiﬁcant predictors of choice.  
‘Degree of symptom control’ of ADHD medication was the attribute most highly valued by parents in both groups. 
Parents of adolescents were nearly ﬁve times more likely to choose medications that demonstrated ‘very much 
improved’ symptoms compared with medications that showed only ‘minimally improved’ symptoms (reference 
level) (OR = 4.85, 95 % CI = 4.28–5.49). For the child group, this preference was even stronger (OR = 6.37, 95 % 
CI = 5.79–7.01). A comparison of the child and adolescent groups showed that the attribute ‘duration of symptom 
control’ of ADHD was approximately equally important for both sets of parents. Parents preferred 12 h of symptom 
control to therapies with a shorter duration of action.  
 
[Table 3 Current treatment and side effect proﬁle of medication by country] 
 
Compared with a duration of symptom control of 4–6 h, both sets of parents were 1.6 times more likely to prefer a 
medication with a duration of symptom control of 12 h (p \ 0.01). The impact of each of the three side effects on 
treatment preferences was similar for the two parent groups. A 1 % increase in the probability of any side effect 
reduced the likelihood of choosing a treatment by 30–50 %. Loss of appetite was considered the most important side 
effect to avoid (adolescent OR = 0.98, 95 % CI = 0.97–0.99; child OR = 0.95, 95 % CI = 0.94–0.96) and sleep 
disturbance was considered the least important (adolescent OR = 0.96, 95% CI = 0.95–0.97; child OR = 0.96, 95 % 
CI = 0.95–0.96) by parents of both groups. Parents of adolescents reported a signiﬁcant preference for a treatment 
with a reduced risk of substance abuse (OR = 0.97, 95% CI = 0.97–0.98). Parents were 30 % less likely to choose a 
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treatment associated with a 10 % increase in the risk of substance abuse. ‘Frequency of medication’ had a signiﬁcant 
but relatively smaller impact on parents’ treatment choices. Treatments that required an additional administration 
per day reduced the likelihood that parents would choose that treatment by 11 % for adolescents (OR = 0.89, 95 % 
CI = 0.83–0.94) and by 14 % for children (OR = 0.86, 95 % CI = 0.82–0.90).  
 
[Table 4 Results of the logit model by adolescent and child groups, in order of importance of attributes (most important to least important) ]
 
 
Inter-country differences  
Table 5 shows the ORs of the signiﬁcant attributes for parents of adolescents and children broken down by country. 
Data in this table demonstrate that parents in each country had different patterns of preferences compared with UK 
parents, who were used   as a reference case for analytical purposes. Parents in different countries assigned 
different levels of importance to different aspects of treatments.  
Adolescent sample  
Spanish, Italian, and French parents all placed less value on the degree of symptom control (Spain, OR = 0.39, 95 % 
CI = 0.26–0.58; Italy, OR = 0.27, 95 % CI = 0.18–0.40; France, OR = 0.38, 95 % CI = 0.25–0.58) across all levels 
compared with parents in Germany, the Netherlands, and the UK. ‘Duration of symptom control’ and ‘potential of 
substance abuse’ were equally important across all countries for parents of adolescents. Dutch and German parents 
were also more concerned than other parents in general about the experience of side effects such as vomiting 
(Netherlands, OR = 0.95, 95 % CI = 0.91–1.00; Germany, OR = 0.92, 95 % CI = 0.87–0.98) and loss of appetite 
(Netherlands, OR = 0.93, 95 % CI = 0.88–0.97; Germany, OR = 0.91, 95 % CI = 0.85–0.97). Dutch and French 
parents of adolescents were more concerned than UK parents about sleep disturbance associated with medication 
(Netherlands, OR = 0.97, 95 % CI = 0.95–0.99; France, OR = 1.03, 95 % CI = 1.01–1.05). For the ‘frequency of 
medication’ attribute, German parents stated a stronger preference (compared with UK parents) to avoid a treatment 
that needed to be taken more than once daily (OR = 0.60, 95 % CI = 0.46–0.79). In contrast, Spanish (OR = 1.37, 95 
% CI = 1.13–1.66), Italian (OR = 1.39, 95% CI = 1.14–1.69), and French (OR = 1.25, 95 % CI = 1.02–1.53) parents 
were less concerned than British parents about the number of times per day that their child required medication.  
Child sample  
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Parents of children in Italy placed less value on the duration and degree of symptom control than British parents 
(this was consistent with the ﬁndings from the adolescent parents). Achieving the best level of symptom control was 
important for parents of children in Spain and the UK, with British parents placing most value on this attribute. 
Dutch and German parents of both groups were most concerned with side effects of medication (vomiting, 
Netherlands: OR = 0.96, 95 % CI = 0.92–0.99; loss of appetite, Germany: OR = 0.97, 95 % CI = 0.95–0.99; sleep 
disturbance, Germany: OR = 0.55, 95 % CI = 0.31–1.00). Dutch parents placed similar importance on the need to 
take more than one tablet per day as British parents (OR = 0.95, 95 % CI = 0.91–0.99). When comparing the two 
groups in Italy, parents of children were less concerned about the need to take more than one tablet per day than 
parents of adolescents (child, OR = 1.06, 95 % CI = 1.02–1.10; adolescent, OR = 1.39, 95 % CI = 1.14–1.69). 
Spanish parents of children placed more value on the best level of symptom control, while the Germans were more 
concerned about loss of appetite as a side effect.  
Discussion  
This study is the ﬁrst large-scale pan-European, cross-national comparison of parental preferences for all stimulant 
treatments for ADHD licensed within Europe. Our analysis considered a broader range of medication attributes than 
has been explored in previous studies, including the degree and duration of ADHD symptom control, treatment side 
effects, and perceived risks and concerns of abuse potential in shaping parental preference for selecting one ADHD 
medication versus another. Information on the participants’ current medication was also collected, which allowed 
comparisons between the hypothetical treatment preferences and the current medication proﬁle. The parent 
preference data were also examined at a country level. These analyses often indicated that preferences of parents in 
the Northern European countries (UK, Germany, and the Netherlands) were similar and these preferences differed 
from those of parents in the Southern European countries (Italy, Spain, and France).  
 
CI conﬁdence interval, OR odds ratio, SE standard error This table shows the ORs of the signiﬁcant attributes by 
country only in each group. In this table, the country is the dependent variable. Only countries that were 
signiﬁcantly different from the UK (reference case) and the attributes that were most important to parents in each 
country are shown. For example, Spanish parents were more concerned than UK parents about the need to take 
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medication more than once per day (OR = 1.37, 95 % CI = 1.13–1.66) 
a 
Countries with a signiﬁcant difference in 
overall patient preference compared with the UK, irrespective of attributes 
b 
UK is base case proﬁle  Parents rated 
symptom control as the most important treatment attribute, with both degree of control and its duration inﬂuential in 
determining preferences. These ﬁndings are consistent with previous work by our group and by Mu¨hlbacher et al. 
[8], which indicated that a long duration of symptom control is important in determining parental preferences when 
they are selecting treatment for ADHD. In the present study, the degree of control was more important than its 
duration. A relatively similar pattern was seen across all countries; however, in absolute terms, there were some 
differences between Northern and Southern European countries. In adolescents, parents from the Northern European 
countries placed more importance on the degree of symptom control. This preference was not reﬂected by the degree 
of symptom control currently experienced in real life by many patients. Although more than 40 % of patients were 
taking once-daily ADHD medications, \25 % of parents reported that the effect of ADHD medication that their child 
was taking during the study lasted for 12 h. The fact that parents were more likely to prefer a medication with a 
longer duration of symptom control suggests that there is a degree of unmet need in relation to this particular 
treatment goal.  
There were some cross-national differences in relation to this second aspect of symptom control and the need/ 
preference for multiple dosing of short-acting medications. Respondents in Southern European countries were less 
concerned about the need to take more than one tablet per day. It is possible that this reﬂects cross-European 
lifestyle differences. Where families take a longer break during the middle of the day for lunch, it may be more 
feasible to administer a second dose of treatment. Parents in Southern European countries, particularly outside of the 
big cities, may be more likely to take a longer break during the day than parents in the Northern European countries. 
A question for manufacturers, therefore, arises as to how new formulations and delivery mechanisms can extend the 
duration of symptom control without leading to an unacceptable increase in side effects like sleep disturbances. A 
similar question is also relevant to clinicians, in terms of how they can combine existing therapies to extend the 
duration of symptom control of the medication. Treatment choices are always based on a balance between the 
positive attributes of treatments and the negative aspects.  
Other attributes of treatment were signiﬁcant drivers of parent choice. The current DCE method allowed 
evaluation of the extent to which parents are willing to trade the beneﬁts of treatments against their risks. In general, 
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despite symptom control being the most important determining factor when it comes to treatment preferences, 
parents were willing to accept some reduction in symptom control in order to avoid even a relatively small increase 
in side effects or risk of substance abuse. Both symptom control and side effects were independently signiﬁcant 
predictors of choice; therefore, it is possible to estimate the marginal rates of substitution between these attributes. 
The data also demonstrate that parents would prefer a treatment with equal efﬁcacy but no associated risk of abuse 
or side effects. Previous studies have reported similar ﬁndings, whereby efﬁcacy was regarded as the most important 
attribute; however, side effects and dosing were also identiﬁed as key aspects of treatment [13, 14].‘Potential of 
treatment abuse’ was considered an important attribute by parents of adolescents. Parents gave this attribute more 
importance than avoidance of side effects such as sleep disturbance and vomiting when choosing a treatment. No 
cross-country differences emerged in the value that parents placed on reducing the risk of abuse potential. Other data 
from the survey (Supplementary Table 1) indicated that parents in Southern European countries were more likely to 
be concerned about the potential for abuse related to treatment than parents in other countries. Higher levels of 
awareness and concern would be expected to translate into a stronger preference to avoid such treatments among 
parents in Southern European countries. The data indicate that this was an important concern for all parents and they 
all placed value on a treatment that avoided the risk of abuse potential. Overall, Dutch and German parents were 
more concerned than parents from other countries about side effects and had a stronger preference to avoid them. 
This was true for both vomiting and loss of appetite. Parents in France, the Netherlands, and Germany also placed 
more value on avoiding treatments that could cause sleep disturbance.  
Some other interesting differences emerged between the parents in the different countries in terms of their experi-
ence of ADHD and the care their children had received. There was evidence of a shorter length of time between the 
ﬁrst appearance of symptoms to the diagnosis of ADHD in Southern European countries. At least in this dataset 
diagnoses were made at a younger age in these countries. Given the sampling approach taken, it is difﬁcult to 
determine whether this difference is a real cultural effect or rather something speciﬁc to the particular samples 
recruited for this study. The analyses also identiﬁed some differences in prescribing patterns. The Northern 
European countries reported higher use of MPH, whereas the Southern European countries reported a more varied 
range of treatments, particularly amphetamine-based and non-stimulant products. This may reﬂect different patterns 
of medication availability and treatment patterns in the different European countries [20].  
There are some important limitations to this study that should be considered when interpreting the results. The 
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sample was obtained through a specialist patient recruitment agency and, therefore, it was a self-selected group that 
may not have been completely representative of the European population. This could bias the ﬁndings and affect the 
results in different ways in different countries. In addition, parents/caregivers who participated in the study may 
have children/adolescents with more severe symptoms, which may partially explain why participants reported a 
higher use of baseline amphetamine in the sample than in the general ADHD population. The mean age at diagnosis 
was lower than expected in this study. This could partially be explained by the fact that diagnosis of ADHD was 
gathered from parents and not conﬁrmed with patient medical records. Thus, the low age of diagnosis may be 
confounded by parental recall bias that cannot be conﬁrmed with patient medical records.  
The fact that the survey was performed online may have precluded some people from taking part, i.e., participants 
with no internet access or who do not know how to use the internet. This may have biased the type of respondents, 
e.g., towards a younger or more educated population, although all efforts were made to recruit a sample repre-
sentative of the population in terms of age and gender in each country. Practical constraints required the research 
team to limit the number of attributes that were included in the DCE in order to avoid an overly complex survey. 
Consequently, the choices that parents were asked to make may be a simpliﬁcation of actual, real-life treatment 
choices. However, the survey was not designed to capture information on all aspects of ADHD treatment; rather, an 
assessment of key factors/attributes that is more meaningful to parents when they are faced with decisions to choose 
the most appropriate therapy among the stimulant class was wanted. In fact, this survey focused on the attributes of 
stimulant medications only and, therefore, there is the possibility that only beneﬁts unique to this speciﬁc class of 
medications were captured. The attribute describing duration was expressed in terms of the number of hours per day 
of symptom control. The attribute did not specify at what time in the day the treatment would provide symptom 
control (e.g. morning or afternoon). This may be an important issue to examine in future studies.  
The ﬁndings of this study may provide insight to clinicians, regulatory bodies and decision makers regarding the 
key attributes that drive patient/parent preferences for the choice of ADHD treatments across countries. Importantly, 
it is acknowledged that poor patient/parent satisfaction with pharmacotherapy may lead to poor adherence to 
treatment, which could have a negative impact on clinical outcomes [2]. Further, our results indicate what 
preferences and attributes should be considered for the development of new ADHD medications. Indeed, the 
disconnection between current treatment options and stated parental preferences suggests the existence of unmet 
needs in the treatment of ADHD.  
15 
 
Conclusions  
This study identiﬁed parent preferences for different aspects of ADHD treatment in six European countries. 
Duration and degree of symptom control were the most important aspects of treatment for parents in all countries; 
however, the ﬁndings revealed cultural differences in the relative importance of other attributes. The DCE data also 
reveal participants’ preferences for attributes in relation to administration, potential of treatment abuse, and 
tolerance of side effects. The DCE method allows clinicians and decision makers to identify the key aspects of 
treatment that are important to parents, which may lead to better tailoring of treatments and improved adherence, 
persistence, and patient/caregiver relevant outcomes.  
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